,

Doxy Bro 500

Contains:

  • Doxofylline IP 400 mg

  • Acebrophylline IP 100 mg
    Therapeutic Class: Bronchodilator + Mucolytic/Anti-inflammatory
    Schedule: Schedule H (Prescription Drug)

Doxy Bro 500 is a dual-action respiratory therapy combining Doxofylline, a novel xanthine derivative with bronchodilator activity, and Acebrophylline, a mucolytic and anti-inflammatory agent. Together, they provide comprehensive relief in patients suffering from asthma, COPD, and other obstructive airway diseases by:

  • Doxofylline: Relaxing bronchial smooth muscles, improving airflow

  • Acebrophylline: Reducing mucus viscosity, facilitating expectoration, and inhibiting inflammation

The combination improves airway patency, reduces dyspnea, and improves lung function, making it ideal for both acute exacerbations and chronic maintenance.

Usage of Doxy Bro 500

  • Chronic Obstructive Pulmonary Disease (COPD)

  • Bronchial asthma

  • Chronic bronchitis with mucus hypersecretion

  • Asthmatic bronchitis

  • Smoker’s cough and mucus retention syndromes

  • As an add-on to inhaled corticosteroids and beta-agonists


Common Side Effects

  • Nausea, vomiting

  • Abdominal discomfort

  • Headache

  • Drowsiness or restlessness (less common with doxofylline than with theophylline)

  • Rare: Allergic skin reactions or dry mouth

Note: Doxofylline has a better safety profile than theophylline with significantly reduced cardiac and CNS stimulation.


Precautions

  • Hepatic or renal impairment: Use with caution and monitor closely

  • Avoid in patients with peptic ulcer disease

  • Use cautiously in patients with a history of seizures

  • Not recommended during pregnancy and lactation unless clearly needed

  • Caution in elderly patients and those with cardiac arrhythmias


Drug Interactions

  • Beta-agonists & corticosteroids: Additive bronchodilation (beneficial)

  • Antibiotics like erythromycin, ciprofloxacin: May affect metabolism

  • CNS stimulants: May increase risk of restlessness

  • Alcohol: May increase sedative effects

  • Doxofylline does not significantly interact with CYP1A2—safer in polypharmacy


Dosage and Administration

  • One tablet twice daily, or as prescribed by the physician

  • Preferably taken after meals to reduce GI irritation

  • Adequate hydration improves mucolytic effectiveness


Storage

  • Store in a cool, dry place below 25°C

  • Protect from moisture and sunlight


Patient Counselling Tips

  • Take the medicine as prescribed, even if symptoms improve

  • Do not crush or chew the tablet

  • Maintain adequate fluid intake to help mucus thinning

  • Report symptoms like palpitations, tremors, or persistent headache

  • Do not use as a substitute for rescue inhalers in acute asthma attacks

Review My Order

0

Subtotal